Journal Pre-proofs



Synthesis of novel 3-(quinazol-2-yl)-quinolines via S_NAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors

Imen Boualia, Abdelmadjid Debache, Raouf Boulcina, Thierry Roisnel, Fabienne Berrée, Joëlle Vidal, Bertrand Carboni

PII: S0040-4039(20)30240-9
DOI: https://doi.org/10.1016/j.tetlet.2020.151805
Reference: TETL 151805

To appear in: *Tetrahedron Letters*

Received Date: 5 January 2020
Revised Date: 29 February 2020
Accepted Date: 4 March 2020

Please cite this article as: Boualia, I., Debache, A., Boulcina, R., Roisnel, T., Berrée, F., Vidal, J., Carboni, B., Synthesis of novel 3-(quinazol-2-yl)-quinolines via S_NAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors, *Tetrahedron Letters* (2020), doi: https://doi.org/10.1016/j.tetlet.2020.151805

Graphical Abstract

Synthesis of novel 3-(quinazol-2-yl)-quinolines via S_NAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors

Leave this area blank for abstract info.

Imen Boualia, Abdelmadjid Debache, Raouf Boulcina,* Thierry Roisnel, Fabienne Berrée, Joelle Vidal,* and Bertrand Carboni



ELSEVIER

Tetrahedron Letters
journal homepage: www.elsevier.com

Synthesis of novel 3-(quinazol-2-yl)-quinolines via S_NAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors

Imen Boualia,[a,b] Abdelmadjid Debache,[a] Raouf Boulcina,[a,c]* Thierry Roisnel, [b] Fabienne Berrée,[b] Joëlle Vidal,[b]* and Bertrand Carboni[b]

[a] *Laboratoire de Synthèse des Molécules d'Intérêts Biologiques, Université des Frères Mentouri-Constantine, 25000 Constantine, Algérie.*
[b] *Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes) - UMR 6226, F-35000 Rennes, France. E-mail: joelle.vidal@univ-rennes1.fr*
[c] *Département des Sciences et Techniques, Faculté de Technologie, Université Mostefa Benboulaïd-Batna 2, 05000 Batna, Algérie. E-mail: r.boulcina@univ-batna2.dz*

ARTICLE INFO

Article history:
Received
Received in revised form
Accepted
Available online

Keywords:
Quinazoline
Quinoline
S_NAr
$AlCl_3$-mediated reaction
Proteasome inhibitor

ABSTRACT

A new series of 3-(quinazol-2-yl)-quinolines was synthesized by S_NAr reaction from easily prepared 4-chloro-2-(2-chloroquinolin-3-yl)quinazolines and a range of phenols and thiophenol as nucleophiles. The $AlCl_3$-mediated C–C bond formation was also successfully exploited to introduce aryl and hereroaryl substituents on one or both heterocyclic units. These procedures afford efficient syntheses of polysubstituted 3-(quinazol-2-yl)-quinolines in few steps and high yields. Some of these polysubstituted 3-(quinazol-2-yl)-quinolines inhibit the human 20S proteasome.

The quinoline core is found in many natural products and has a privileged role in drug discovery.[1] For example, camptothecin, topotecan, belotecan or cabozatinib, that inhibit topoisomerase or tyrosine kinases, are currently approved as anticancer treatment. Quinoline scaffold has also been used in the search for inhibitors of other important cancer targets, such as tubulin polymerization, DNA repair and proteasome.[1-2] In the field of proteasome, quinolines are also widely represented as depicted in Figure 1.[3] Such derivatives could overcome some problems encountered with the pharmacodynamic and pharmacokinetic profiles of the proteasome inhibitors currently approved in cancer therapy (bortezomib, carfilzomib and ixazomib), usually attributed to their peptide structure and the presence of an electrophilic warhead.[2b] In the wide family of quinolines derivatives, hybrids which combines this scaffold with a quinazoline moiety, another important heterocycle possessing significant biological activities,[4] are poorly exemplified (Fig. 2).



Fig.1 Structures of proteasome inhibitors bearing a quinoline scaffold (A. inhibitor of the proteasome 19S particle; B. inhibitors of the proteasome 20S core particle).

They were mostly synthesized by palladium-catalyzed carbonylation of 2-aminobenzylamine and 2-bromoquinoline,[5] Suzuki coupling of the chloroquinazolinone with 2-quinolyl boronic acid,[6] or DMAP-catalyzed one-pot three-component reaction from 2-formylquinolines, 2-aminobenzophenones and ammonium acetate.[7]

In continuation of our research program centered on the design and synthesis of potentially bioactive molecules [8] and, as part of our studies on non-peptide and non-covalent 20S proteasome inhibitors,[3h,9] we here focus on the preparation of a series of novel hybrid 3-(quinazol-2yl)-quinolines **6-15** via S_NAr and $AlCl_3$ induced (hetero) arylation reactions of **5** and their 20S proteasome inhibition evaluation (Fig. 2).



Fig.2 Targeted 3-(quinazol-2yl)-quinolines **6-15** and their precursor **5**.

To access to our common building blocks **5**, intermediates **3a-c** were first prepared in high yields by using procedures previously reported in our laboratory.[8c] Couplings of the 2-aminobenzamide **1** with appropriate quinoline-3-carboxaldehydes **2** were carried out in the presence of K_2CO_3 in DMF at 80 °C (Scheme 1). On treatment with iodine in DMF at 80 °C, **3a-c** exclusively gave the desired oxidized product **4a-c** in 76-86% yields. Chlorination was then readily achieved with phosphorus oxychloride giving **5a-c** in 70-78% yields.



Scheme 1 Reagents and conditions: (a) K_2CO_3, DMF, 80° C, 3h, **3a** (94%), **3b** (91%) **3c** (90%); (b) I_2, DMF, 80° C, 6h, **4a** (76%), **4b** (84%), **4c** (86%); (c) $POCl_3$, reflux, 18h, **5a** (76%), **5b** (78%), **5c** (70%).

Based on our previous study related to the synthesis of 4-anilinoquinolino-quinazoline hybrids using S_NAr reactions with various aromatic amines,[8c] we then decided to use phenols as nucleophiles. With 1 equiv. under refluxed acetonitrile in the presence of K_2CO_3, the corresponding adducts **6a-h** were isolated in high yields (Table 1). A complete conversion occurred within a short time (2 h) with no substitution at the C-2 position of the quinoline. This high regioselectivity at the C-4 position was confirmed by X-ray diffraction of **6b** that reveals a dihedral angle of 50° between the quinazoline and the quinoline subunits.[10] Similarly, the 4-phenylthio derivative **6i** was synthesized from thiophenol and **5a** in 83% isolated yield.

On the other hand, when the reaction of **5a** was performed with two equivalents of phenol under the same conditions, the formation of disubstituted quinazoline derivatives did not occur at all even after 16 h in CH_3CN under reflux. However, modest yields of **7a-d** (23 to 53%) were obtained by performing the reactions in refluxing DMF within 16 h (Table 2).

Table 1
Synthesis of 2-chloro-3-(4-aryloxyquinazol-2-yl)-quinolines **6**



	R	X	Ar	Yield
6a	Me	O	C_6H_5	84%
6b	Me	O	4-Me-C_6H_4	92%
6c	Me	O	3-MeO-C_6H_4	88%
6d	Me	O	1-naphthyl	93%
6e	Me	O	4-NO_2-C_6H_4	71%
6f	Me	O	3-pyridyl	63%
6g	OMe	O	4-Me-C_6H_4	89%
6h	H	O	4-Me-C_6H_4	80%
6i	Me	S	C_6H_5	83%

To extend the range of available compounds, the reactions between compounds **6** and *p*-toluidine, selected as model aniline, were also examined. Aminoquinolines **8a-c** were then prepared in good yields after one hour in refluxed *i*-PrOH in the presence of 1N HCl (Table 3). NMR and mass spectra of **6a-i**, **7a-c** and **8a-c** are in full agreement with the proposed structures. It is worthy to note the downfield shift of the NH signal in the ^1H NMR spectra of compounds **8** which would indicate that NH is located in an aromatic deshielding area of the twisted structure.

Table 2
Synthesis of 2-aryloxy-3-(4-aryloxyquinazol-2-yl)-quinolines **7**



Compound	R	Ar	Yield
7a	Me	phenyl	23%
7b	Me	4-Me-C_6H_4	52%
7c	H	4-Me-C_6H_4	53%
7d	OMe	4-Me-C_6H_4	43%

We then turned our attention to the formation of a new carbon-carbon bond. Introduction of an aryl or heteroaryl moiety at C-2 of quinoline ring or C-4 of quinazoline was frequently carried out via Ni-catalyzed reaction of quinolone with arylzinc,[11]

quinoline *N*-oxide with indole.[12]

Table 3
Synthesis of 2-arylamino-3-(4-aryloxyquinazol-2-yl)-quinolines **8**



Compound	Ar	Yield
8a	C_6H_5	88%
8b	4-Me-C_6H_4	62%
8c	1-naphthyl	72%

Despite the merit of these protocols, they are not free from limitations in terms of longer reaction time, use of costly catalysts, requirement of stringent conditions or multistep synthesis of starting materials. Over the last few years, the C–C bond forming reactions between heteroaryl chlorides containing a C(Cl)=N moiety and various electron rich arenes or heteroarenes in the presence of $AlCl_3$ have been reported on several occasions.[13] 2-Chloro-3-(4-(het)arylquinazol-2-yl)-quinolines **9a-c** were effectively obtained under this catalytic conditions in excellent yields from 2,4,6-trimethoxybenzene, indole and pyrrole (Scheme 2). Notably, as previously observed for S_NAr reactions, no 2-substituted quinoline adducts were detected. In view of the mechanism generally proposed for this reaction,[13g] this regioselectivity could be explained by the favored complexation of $AlCl_3$ to the quinazoline nitrogen. However, the use of an excess of 2,4,6-trimethoxybenzene with **5b** as substrate, for 15h instead of 3h, afforded the desired bi-substituted derivative **10**.



Scheme 2 Reagents and conditions: (a) (Het)ArH, $AlCl_3$, DCE, 80 °C, 3h, **9a** (83%), **9b** (71%), **9c** (91%); (b) 1,3,5-trimethoxybenzene, $AlCl_3$, DCE, 80 °C, 15h, **10** (61%)

Finally, because morpholines are privileged substitiuents abundantly used as in drugs and medicinal chemistry,[14] we applied the above-described methodologies to the synthesis of new derivatives presenting a morpholino substituent on the quinazoline or (and) quinoline parts. For example, in the presence was completed in methylene chloride at 45°C within 2h. With morpholine as solvent, at 80 °C for 1h, **12b** and **12c** were obtained in 88 and 84% yields, respectively (Scheme 3). Under the same conditions, were synthesized **13-15** with 2,4,6-trimethoxyphenyl, indolyl and pyrrolyl moieties at the 4-position of quinazolines.



Scheme 3 Reagents and conditions: (a) morpholine (2 equiv), CH_2Cl_2, 45° C, 2h, 11 (91%); (b) morpholine (solvent), 80°C, 1h, **12b** (R = Me, 88%), **12c** (R = OMe, 84%); (c) (Het)ArH, $AlCl_3$, 80°C, $(CH_2Cl)_2$, 3h, then morpholine (2 equiv), CH_2Cl_2, 45° C, 2h, **13** (Ar = 2,4,6-trimethoxyphenyl, 92%), **14** (Het = indol-3-yl 78%), **15** (Het = pyrrol-3-yl, 79%).

Having in hands a small library of 3-(quinazol-2-yl)-quinolines **6-15**, we evaluated their biological activities as inhibitors of the purified human constitutive 20S proteasome. The ability to inhibit the three proteolytic activities, ChT-L, T-L and PA, was measured by fluorescence. Owing to their weak (**7c**, **9a**, **9b**, **9c**, **13**) or moderate fluorescence (**7d**) at the working wavelengths, these compounds were excluded from the screening.

Ten compounds over 18 inhibited fairly (20%) to strongly (90%) the ChT-L or the PA activities at 50 µM (Fig.3 A.). The T-L activity was fairly inhibited by 4 products. Compounds that gave more than 70% inhibition were further characterized by their effect-dose response (Fig. S1 in supplementary material) to determine concentrations giving 50% inhibition (IC_{50}, table 4). As for the quinoline 20S proteasome inhibitors saquinavir,[3b] **5-AHQ**[3f] and **III**[3j] (Fig. 1), the best compound **6e** inhibits both ChT-L and PA activities, with a similar potency for PA and a lower one for ChT-L.

Table 4
IC_{50} (µM) values for inhibition of human constitutive CP (pH 8, 37 °C)

	6e	**6f**	**11**	**12b**	chloroquine
ChT-L activity	35.4 ± 0.6	19 ± 1	44 ± 1	41 ± 1	6.3 ± 0.4
PA activity	13.2 ± 0.6	*66%*[a]	*55%*[a]	34.2 ± 0.8	22.5 ± 0.6

[a] % inhibition at 50 µM

compound **6e** (Fig. S2 and Fig. S3 in supplementary material).[15] A competitive inhibition of the ChT-L activity was observed.[15] This indicates that inhibitor **6e** binds exclusively to the free enzyme with an inhibition constant Ki = 19 ± 1 µM. Such a competitive inhibition mechanism has been reported mainly for the ChT-L activity of non-covalent peptide derivatives[16] and also for the PA activity of tamoxifen derivatives.[17] The PA activity was inhibited non-competitively.[15] Inhibitor **6e** binds with an equal affinity to the enzyme alone or the enzyme in complex with the substrate (K_i = K'_i = 13.2 ± 0.6 µM). Non-competitive inhibition of 20S proteasome has been observed for the PA activity of quinoline **5-AHQ** (Fig.1),[3f] and for the ChT-L activity of oxadiazoles,[9a] tamoxifen derivatives[17] or peptide derivatives.[16a,18]



Fig.3 Effect of 3-(quinazol-2-yl)-quinolines **6-15** on human constitutive CP (pH 8, 37 °C)**.** Compared inhibitions of the ChT-L, PA and T-L activities by compounds **6-15** at 50 µM.

The many crystallographic structures of inhibitors in complex with 20S proteasome have provided a deep understanding of the binding channel and specificity pockets that can be targeted by competitive inhibitors.[19] However a non-competitive modulation of 20S proteasome suggests that binding to other sites could occur while blocking 20S proteasome activities. As yet, the only direct evidences (NMR[3e] or X-ray[20]) for such a mechanism involving non-peptide derivatives have been brought using quinoline derivatives (respectively chloroquine or **I**).

We described in this paper an efficient synthesis of poly-substituted 3-(quinazol-2-yl)-quinoline derivatives **6-15** in few steps and high yields. Chemical diversity was introduced by selective mono or double S_NAr of a range of phenols, thiophenol, amines or anilines with the easily prepared di-chloro derivatives **5**. Aryl or heteroaryl carbon nucleophiles allowed the $AlCl_3$ mediated and controlled creation of one or two C-C bonds.

Several 3-(quinazol-2-yl)-quinoline derivatives inhibited the ChT-L and PA activities of the human constitutive 20S proteasome. The best compound **6e** inhibited these activities by different mechanisms, with moderate affinities (Ki = 13-19 µM).

Acknowledgments

This work was supported by the University of Rennes 1 and the Centre National de la Recherche Scientifique (CNRS). IB gratefully acknowledges le Ministère de l'Enseignement Supérieur et de la Recherche Scientifique (Algeria) and The Algerian-French scholarship program PROFAS B+.

Supplementary Material

Supplementary data to this article can be found online at

[1] (a) Solomon, V. R.; Lee, H. *Curr. Med. Chem.* **2011,** *18*, 1488-1508;
(b) Musiol, R. *Expert Opin. Drug Discov.* **2017,** *12*, 583-597.
[2] (a) Manasanch, E. E.; Orlowski, R. Z. *Nat. Rev. Clin. Oncol.* **2017,** *14*, 417;
(b) Park, J. E.; Miller, Z.; Jun, Y.; Lee, W.; Kim, K. B. *Translational Research* **2018,** *198*, 1-16.
[3] (a) Perez, C.; Li, J.; Parlati, F.; Rouffet, M.; Ma, Y.; Mackinnon, A. L.; Chou, T.-F.; Deshaies, R. J.; Cohen, S. M. *J. Med. Chem.* **2017,** *60*, 1343-1361;
(b) Pajonk, F.; Himmelsbach, J.; Riess, K.; Sommer, A.; McBride, W. H. *Cancer Res.* **2002,** *62*, 5230-5235;
(c) Mao, X.; Li, X.; Sprangers, R.; Wang, X.; Venugopal, A.; Wood, T.; Zhang, Y.; Kuntz, D. A.; Coe, E.; Trudel, S.; Rose, D.; Batey, R. A.; Kay, L. E.; Schimmer, A. D. *Leukemia* **2009,** *23*, 585-590;
(d) Zhai, S.; Yang, L.; Cui, Q. C.; Sun, Y.; Dou, Q. P.; Yan, B. *JBIC, J. Biol. Inorg. Chem.* **2010,** *15*, 259-269;
(e) Ruschak, A. M.; Kay, L. E. *Proc. Natl. Acad. Sci. U. S. A.* **2012,** *109*, E3454-E3462, SE3454/1-SE3454/31;
(f) Li, X.; Wood, T. E.; Sprangers, R.; Jansen, G.; Franke, N. E.; Mao, X.; Wang, X.; Zhang, Y.; Verbrugge, S. E.; Adomat, H.; Li, Z. H.; Trudel, S.; Chen, C.; Religa, T. L.; Jamal, N.; Messner, H.; Cloos, J.; Rose, D. R.; Navon, A.; Guns, E.; Batey, R. A.; Kay, L. E.; Schimmer, A. D. *J. Natl. Cancer Inst.* **2010,** *102*, 1069-1082;
(g) Pundir, S.; Vu, H.-Y.; Solomon, V. R.; McClure, R.; Lee, H. *Cancer Research* **2015,** *75*, 4164-4175;
(h) Basse, N.; Montes, M.; Marechal, X.; Qin, L.; Bouvier-Durand, M.; Genin, E.; Vidal, J.; Villoutreix, B. O.; Reboud-Ravaux, M. *J. Med. Chem.* **2010,** *53*, 509-513;
(i) Di Giovanni, C.; Ettari, R.; Sarno, S.; Rotondo, A.; Bitto, A.; Squadrito, F.; Altavilla, D.; Schirmeister, T.; Novellino, E.; Grasso, S.; Zappala, M.; Lavecchia, A. *Eur. J. Med. Chem.* **2016,** *121*, 578-591;
(j) McDaniel, T. J.; Lansdell, T. A.; Dissanayake, A. A.; Azevedo, L. M.; Claes, J.; Odom, A. L.; Tepe, J. J. *Bioorg. Med. Chem.* **2016,** *24*, 2441-2450.
[4] Alagarsamy, V.; Chitra, K.; Saravanan, G.; Solomon, V. R.; Sulthana, M. T.; Narendhar, B. *Eur. J. Med. Chem.* **2018,** *151*, 628-685.
[5] Chen, J.; Natte, K.; Neumann, H.; Wu, X.-F. *RSC Adv.* **2014,** *4*, 56502-56505.
[6] Sutherland, H. S.; Hwang, I. Y.; Marshall, E. S.; Lindsay, B. S.; Denny, W. A.; Gilchrist, C.; Joseph, W. R.; Greenhalgh, D.; Richardson, E.; Kestell, P.; Ding, A.; Baguley, B. C. *Invest New Drugs* **2012,** *30*, 2035-45.
[7] Derabli, C.; Boulcina, R.; Kirsch, G.; Carboni, B.; Debache, A. *Tetrahedron Lett.* **2014,** *55*, 200-204.
[8] (a) Mahdjoub, S.; Boulcina, R.; Yildirim, M.; Lakehal, S.; Boulebd, H.; Debache, A. *Synth. Commun.* **2018,** *48*, 2366-2381;
(b) Derabli, C.; Boualia, I.; Abdelwahab, A. B.; Boulcina, R.; Bensouici, C.; Kirsch, G.; Debache, A. *Bioorg. Med. Chem. Lett.* **2018,** *28*, 2481-2484;
(c) Derabli, C.; Boulcina, R.; Kirsch, G.; Debache, A. *Tetrahedron* **2017,** *73*, 351-358.
[9] (a) Maréchal, X.; Genin, E.; Qin, L.; Sperandio, O.; Montes, M.; Basse, N.; Richy, N.; Miteva, M. A.; Reboud-Ravaux, M.; Vidal, J.; Villoutreix, B. O. *Curr. Med. Chem.* **2013,** *20*, 2351-2362;
(b) Villoutreix, B. O.; Khatib, A. M.; Cheng, Y.; Miteva, M. A.; Marechal, X.; Vidal, J.; Reboud-Ravaux, M. *Oncotarget* **2017,** *8*, 10437-10449.
[10] CCDC 1871916 contains the crystallographic data for compounds **6b**.These data can be obtained free of charge

www.ccdc.cam.ac. uk/data_request/cif.
[11] (a) Tobisu, M.; Hyodo, I.; Chatani, N. *J. Am. Chem. Soc.* **2009,** *131*, 12070-12071;
(b) Fleckenstein, C. A.; Plenio, H. *Chem. Eur. J.* **2008,** *14*, 4267-4279.
[12] Hoemann, M. Z.; Kumaravel, G.; Xie, R. L.; Rossi, R. F.; Meyer, S.; Sidhu, A.; Cuny, G. D.; Hauske, J. R. *Bioorg; Med. Chem. Lett.* **2000,** *10*, 2675-2678.
[13] (a) Pal, M.; Batchu, V. R.; Parasuraman, K.; Yeleswarapu, K. R. *J. Org. Chem.* **2003,** *68*, 6806-6809;
(b) Pal, M.; Batchu, V. R.; Dager, I.; Swamy, N. K.; Padakanti, S. *J. Org. Chem.* **2005,** *70*, 2376-2379;
(c) Kodimuthali, A.; T. C, N.; Prasunamba, P. L.; Pal, M. *Tetrahedron Lett.* **2009,** *50*, 354-358;
(d) Kodimuthali, A.; Chary, B. C.; Prasunamba, P. L.; Pal, M. *Tetrahedron Lett.* **2009,** *50*, 1618-1621;
(e) Kumar, K. S.; Chamakuri, S.; Vishweshwar, P.; Iqbal, J.; Pal, M. *Tetrahedron Lett.* **2010,** *51*, 3269-3273;
(f) Rajasekhar, M.; Rao, K. U. M.; Sundar, C. S.; Reddy, N. B.; Kumar Nayak, S. K.; Reddy, C. S. *Chem. Pharm. Bull* **2012,** *60*, 854;
(g) Sunke, R.; Nallapati, S. B.; Kumar, J. S.; Shiva Kumar, K.; Pal, M. *Org. Biomol. Chem.* **2017,** *15*, 4042-4057.
[14] (a) Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. *J. Med. Chem.* **2014,** *57*, 5845-5859;
(b) Vitaku, E.; Smith, D. T.; Njardarson, J. T. *J. Med. Chem.* **2014,** *57*, 10257-10274;
(c) Ritchie, T. J.; Macdonald, S. J. F.; Peace, S.; Pickett, S. D.; Luscombe, C. N. *MedChemComm* **2012,** *3*, 1062-1069.
[15] Bisswanger, H.; Wiley-VCH Verlag GmbH & Co: Weinheim, 2008.
[16] (a) Desvergne, A.; Genin, E.; Maréchal, X.; Gallastegui, N.; Dufau, L.; Richy, N.; Groll, M.; Vidal, J.; Reboud-Ravaux, M. *J. Med. Chem.* **2013,** *56*, 3367-3378;
(b) Maréchal, X.; Pujol, A.; Richy, N.; Genin, E.; Basse, N.; Reboud-Ravaux, M.; Vidal, J. *Eur. J. Med. Chem.* **2012,** *52*, 322-7;
(c) Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. *J. Antibiot.* **2000,** *53*, 105-9.
[17] Hasegawa, M.; Yasuda, Y.; Tanaka, M.; Nakata, K.; Umeda, E.; Wang, Y.; Watanabe, C.; Uetake, S.; Kunoh, T.; Shionyu, M.; Sasaki, R.; Shiina, I.; Mizukami, T. *Eur. J. Med. Chem.* **2014,** *71*, 290-305.
[18] (a) Myung, J.; Kim, K. B.; Lindsten, K.; Dantuma, N. P.; Crews, C. M. *Mol. Cell* **2001,** *7*, 411-420;
(b) Santos, R. d. L. A.; Bai, L.; Singh, P. K.; Murakami, N.; Fan, H.; Zhan, W.; Zhu, Y.; Jiang, X.; Zhang, K.; Assker, J. P.; Nathan, C. F.; Li, H.; Azzi, J.; Lin, G. *Nat. Commun.* **2017,** *8*, 1692;
(c) Karpowicz, P.; Osmulski, P. A.; Witkowska, J.; Sikorska, E.; Gizynska, M.; Belczyk-Ciesielska, A.; Gaczynska, M. E.; Jankowska, E. *PLoS One* **2015,** *10*, e0143038.
[19] Borissenko, L.; Groll, M. *Chem. Rev.* **2007,** *107*, 687-717.
Int. Ed. **2015,** *54*, 11275-11278.

Graphical Abstract

Highlights:

- A new series of polysubstituted 3-(quinazol-2-yl)-quinolines have been synthesized by SNAr reaction.
- Various amines, phenols and thiophenol have been used as reactants.
- $AlCl_3$ has mediated C–C bond forming reactions.
- The methodology can be viewed as a useful alternative to the Suzuki reactions.
- Some of the synthesized 3-(quinazol-2-yl)-quinolines inhibit the human 20S proteasome.

Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Synthesis of novel 3-(quinazol-2-yl)-quinolines via S_NAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors

Leave this area blank for abstract info.

Imen Boualia, Abdelmadjid Debache, Raouf Boulcina,* Thierry Roisnel, Fabienne Berrée, Joelle Vidal,* and Bertrand Carboni